Saturday 17 October 2026 Export PTHS’s income statement to Excel — free account

Pelthos Therapeutics Inc.

In the quarter to June 2026, EPS fell 23.1%, free cash flow fell 1,615.0% and total debt rose 2,692.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

20.15 0.11 −0.54%

Follow PTHS

Alert me

Market cap: $77.6M
P/E: 0.0×
Fwd P/E: −2.3×
Dividend yield: —
F-score: n/a
Altman Z: −0.75
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.00

Total sells 0.49

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	—	—	—
Sell	1	—	—	—	—	4	1	1	3	—	—	3

Insider Ownership 52.25%

Capital & Financial Ratios $m

Market Cap 77.57

Revenue 43.30

Net Income (86.39)

Free Cash Flow (42.60)

Net Debt 45.35

Current Ratio 1.98

Debt/Equity (46.58)

P/E ratio 0.00

Fwd P/E (2.34)

P/S ratio 1.65

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 29.68%

Next Y EPS Growth 73.92%

Next Y revenue growth (62.45%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	0	1	18	25
Receivables	—	—	9	14
Inventory	—	—	24	21
Other	—	—	—	—
	0	1	53	63

	2023	2024	2025	Q'26
Payables	5	2	3	6
ST’ Debt	1	2	—	—
Other	0	—	6	4
	7	4	26	32

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11	16	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(8)	—	—	—
’25	(1)	0	(15)	(6)	(23)
’24	(2)	(3)	0	(1)	(6)
’23	0	0	0	0	(1)
’22	—	—	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(8)	—	—	—
’25	(1)	0	(15)	(6)	(23)
’24	(2)	(3)	0	(1)	(6)
’23	0	0	0	0	(1)
’22	—	—	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(7.57)	(6.62)	—	—	—
’25	(3.20)	(5.38)	(5.30)	(9.23)	(23.04)
’24	(5.50)	(3.10)	(2.90)	(3.20)	(14.30)
’23	(8.70)	(9.50)	(14.43)	(25.16)	(57.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	4.50	6.30	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	—	60.00	54.29
People
People	Employees	—	—	—	—	—	—	—	4	11	92
	Revenue/emp, $m	—	—	—	—	—	—	—	0.00	0.00	0.18
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	17
	Gross margin, %	—	—	—	—	—	—	—	—	—	76.25
	EBT	—	—	—	—	—	(1)	(2)	(7)	(8)	(51)
	EBT margin, %	—	—	—	—	—	0.00	0.00	0.00	0.00	(301.91)
	Net income	—	—	—	—	—	(1)	(2)	(7)	(8)	(43)
	Depreciation	—	—	—	—	—	—	0	0	1	3
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	0.00	0.00	0.00	8.93
	Earnings	—	—	—	—	—	—	(56.52)	(57.80)	(14.30)	(23.04)
	Cash flow	—	—	—	—	—	0.00	(36.03)	(7.68)	(10.39)	(12.01)
	Capex	—	—	—	—	—	—	0.00	0.00	0.00	(0.05)
	Free cash flow	—	—	—	—	—	0.00	(36.03)	(7.68)	(10.39)	(12.07)
	Book value	—	—	—	—	—	0.00	(85.21)	(50.47)	(4.87)	20.68
	Shares, m	—	—	—	—	—	—	0	0	1	2
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	0.00
	P/S	—	—	—	—	—	—	—	—	—	0.00
	P/B	—	—	—	—	—	—	—	—	—	1.50
	EV/Sales	—	—	—	—	—	—	—	—	—	0.00
	EV/FCF	—	—	—	—	—	—	—	—	—	(3.28)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(2)	(2)	(1)	(6)	(23)
	Capex	—	—	—	—	—	—	—	—	—	0
	Free cash flow	—	—	—	—	—	(2)	(2)	(1)	(6)	(23)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	(3)	(4)	(6)	(3)	27
	Total debt	—	—	—	—	—	—	1	1	2	31
	Net debt	—	—	—	—	—	—	0	1	2	13
	Shareholders’ equity	—	—	—	—	—	(4)	(4)	(6)	(3)	39
Returns, %
Returns, %	ROA	—	—	—	—	—	0.00	(8,924.14)	(9,743.63)	(1,085.71)	(65.75)
	ROIC	—	—	—	—	—	0.00	0.00	0.00	0.00	(38.76)
	ROE	—	—	—	—	—	0.00	66.57	145.42	173.72	(239.55)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NMRA Neumora Therapeutics, Inc.	$80.2M	— (loss-making)	—	—	n/m	+24.45% (above 0%: growing)	0.00%	0.00%	Compare
CLLS Cellectis S.A.	$79.9M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)	Compare
PMN Promis Neurosciences	$78.0M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
PTHS Pelthos Therapeutics Inc.	$77.6M	— (loss-making)	— (loss-making)	—	n/m	−1,614.99% (below 0%: shrinking)	76.86%	(111.02%)
TELO Telomir Pharmaceuticals, Inc.	$77.3M	— (loss-making)	—	—	n/m	−45.34% (below 0%: shrinking)	—	0.00%	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
CRDF Cardiff Oncology, Inc.	$75.5M	— (loss-making)	— (loss-making)	−14.05% (below 0%: shrinking)	n/m	−41.36% (below 0%: shrinking)	100.00%	(9,245.19%)	Compare
ACRV Acrivon Therapeutics, Inc.	$75.4M	— (loss-making)	—	—	n/m	+12.59% (above 0%: growing)	0.00%	0.00%	Compare
OKYO OKYO Pharma Limited Sponsored ADR	$75.1M	— (loss-making)	—	—	n/m	+37.39% (above 0%: growing)	0.00%	—	Compare
Median of peers	$76.8M	—	—	−21.89%	—	−12.18%	0.00%	0.00%

All 614 Biotechnology stocks →

Pelthos Therapeutics Inc. (PTHS) key facts

Pelthos Therapeutics Inc. (PTHS) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, PTHS traded at $20.15, a market capitalization of $77.6 million.
Return on equity was −239.6% and debt-to-equity -46.58.
Its Altman Z-score is −0.75 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.